<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03801122</url>
  </required_header>
  <id_info>
    <org_study_id>2018-1201</org_study_id>
    <secondary_id>2018-004756-38</secondary_id>
    <nct_id>NCT03801122</nct_id>
  </id_info>
  <brief_title>Evolution of Thromboelastography During Tranexamic Acid Treatment</brief_title>
  <acronym>TTRAP-Bleeding</acronym>
  <official_title>Study of Thromboelastography During Tranexamic Acid Treatment in Preventing Bleeding in Patients With Haematological Malignancies Presenting Severe Thrombocytopenia (TTRAP-bleeding)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de la Loire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with hematological malignancies are at increased risk of bleeding, especially during
      intensive chemotherapy. The aim of this study is to compare by thromboelastography changes
      during the intensive chemotherapy in patients with hematological malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with hematological malignancies often develop low platelet counts either as a
      consequence of the disease or the treatment by chemotherapy or stem cell transplantation.
      Platelet transfusions are commonly given to raise any low platelet count and reduce the risk
      of clinical bleeding (prophylaxis) or stop active bleeding (therapy). The last studies have
      showed that many patients continue to experience bleeding, despite the use of platelet
      transfusions. Tranexamic acid is an antifibrinolytic agent. It reduces the breakdown of clots
      formed. This treatment is widely used in medicine (e.g. emergency, surgery, post-partum) and
      decreases blood loss and the use of red cell transfusions. The purpose of this study is to
      test different doses of tranexamic acid (full dose: 3g/day and half dose (1.5g/day) and to
      study its effect by thromboelastography, with the aim to determine the optimal posology for
      further clinical studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1 : Tranexamic acid 3g/day Arm 2 : Tranexamic acid 1.5g/day Arm 3 : No tranexamic acid</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of amplitude observed in thromboelastography</measure>
    <time_frame>30 days</time_frame>
    <description>Amplitude levels observed in thromboelastography will be reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time at the beginning of the clot</measure>
    <time_frame>30 minutes</time_frame>
    <description>Time at the beginning of the clot will be reported in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clot formation time</measure>
    <time_frame>30 minutes</time_frame>
    <description>Clot formation time will ne reported in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha angle</measure>
    <time_frame>30 days</time_frame>
    <description>Alpha angle will be measured in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of lysis after 30min</measure>
    <time_frame>30 minutes</time_frame>
    <description>Percentage of lysis after 30min will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing bleeding of WHO (World Health Organisation ) grade 2 or above</measure>
    <time_frame>30 days</time_frame>
    <description>Proportion of patients experiencing bleeding of WHO (World Health Organisation ) grade 2 or above will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Number of adverse events will be reported</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Hematological Malignancies Treated With Intensive Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid 3g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of tranexamic acid 3g/day, with 3 injections/8 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic acid 1.5g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of tranexamic acid 1.5g/day, with 3 injections/8 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment (no administration of tranexamic acid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>Administration of tranexamic acid, with 3 injections/8 hours.</description>
    <arm_group_label>Tranexamic acid 1.5g/day</arm_group_label>
    <arm_group_label>Tranexamic acid 3g/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient affiliated to a social security regimen or beneficiary of the same

          -  Signed written informed consent form

          -  Confirmed diagnosis of a hematological malignancy and undergoing intensive
             chemotherapy

          -  Expected to experience hypoproliferative thrombocytopenia resulting in a platelet
             count of ≤10 G/L for ≥ 5 days

        Exclusion Criteria:

          -  Pregnant women

          -  Patient under guardianship or deprived of his liberty or any condition that may affect
             the patient's ability to understand and sign the informed consent

          -  Refractoriness to platelet transfusion or requirement for a specific type of platelet
             transfusion (ABO-compatible, plasma-free)

          -  Ongoing anticoagulant therapy or antiplatelet therapy at the time of enrolment

          -  Treatment with any pro-coagulant agent within 48 hours of enrolment, or enrolment in
             other trials involving platelet transfusions, platelet growth factors, or presentation
             of a known hypercoagulable state

          -  Diagnosis of arterial or venous thromboembolic disease within the previous year

          -  Patient experiencing a bleeding event WHO grade ≥ 2 within 7 days before inclusion

          -  contra-indications to tranexamic acid (allergy, history of seizures, creatinine
             clearance &lt; 30 mL/min)

          -  Refusing participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie Chalayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie Lucien Neuwirth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie Chalayer, MD</last_name>
    <phone>0477917089</phone>
    <phone_ext>+33</phone_ext>
    <email>emilie.chalayer@icloire.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Daguenet, PhD</last_name>
    <phone>0477917089</phone>
    <phone_ext>+33</phone_ext>
    <email>elisabeth.daguenet@icloire.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Chalayer, MD</last_name>
      <phone>0477917089</phone>
      <phone_ext>+33</phone_ext>
      <email>emilie.chalayer@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Emilie Chalayer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme Cornillon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Guyotat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle Tavernier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Lejeune, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fressia Honeyman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2019</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tranexamic acid</keyword>
  <keyword>bleeding</keyword>
  <keyword>hematological malignancies</keyword>
  <keyword>thrombocytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

